Effectiveness of etanercept in bleomycin-induced experimental scleroderma

Objectives. To evaluate the effects of etanercept and thalidomide in the mouse model of bleomycin-induced scleroderma (BLM-IS). Methods. This study involved four groups (n = 8 mice in each group). Dermal sclerosis was induced by repeated subcutaneous injections of BLM (10 μg) for 4 weeks in BALB/c m...

Full description

Saved in:
Bibliographic Details
Published in:Rheumatology (Oxford, England) England), 2008-02, Vol.47 (2), p.172-175
Main Authors: Koca, S. S., Isik, A., Ozercan, I. H., Ustundag, B., Evren, B., Metin, K.
Format: Article
Language:English
Subjects:
Animal model
Animals
Antibacterial agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antirheumatic Agents - therapeutic use
Biological and medical sciences
Bleomycin
Cytokines - blood
Disease Models, Animal
Etanercept
Female
Hydroxyproline - metabolism
Immunoglobulin G - therapeutic use
Immunomodulators
Medical sciences
Mice
Mice, Inbred BALB C
Pharmacology. Drug treatments
Receptors, Tumor Necrosis Factor - therapeutic use
Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis
Scleroderma
Scleroderma, Localized - chemically induced
Scleroderma, Localized - drug therapy
Scleroderma, Localized - pathology
Skin - drug effects
Skin - metabolism
Skin - pathology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives. To evaluate the effects of etanercept and thalidomide in the mouse model of bleomycin-induced scleroderma (BLM-IS). Methods. This study involved four groups (n = 8 mice in each group). Dermal sclerosis was induced by repeated subcutaneous injections of BLM (10 μg) for 4 weeks in BALB/c mice. Control group received only phosphate-buffered saline. The second group received only BLM; the third and fourth groups were also given an intraperitoneal injection of 100 μg etanercept or 150 mg/kg thalidomide, respectively. Results. BLM increased serum TGF-β1, tissue hydroxyproline levels and expression of α-smooth muscle actin (α-SMA), and dermal fibrosis was histopathologically prominent. Although thalidomide had no significant effect, etanercept caused decreases in levels of serum TGF-β1, tissue hydroxyproline and number of α-SMA-positive cells. Conclusion. Inhibition of TNF-α with etanercept in BLM-IS was resulted in a significant reduction of the dermal sclerosis, collagen accumulation and the number of infiltrating myofibroblastic cells. TNF-α may play a key role in the progression of BLM-IS and TNF-α antagonists may be useful in the management of scleroderma.
ISSN:1462-0324
1462-0332
DOI:10.1093/rheumatology/kem344